OnKure Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for OnKure Therapeutics, Inc. (OKUR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are OKUR insiders buying or selling?
In the last 12 months, OnKure Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 8 sales ($5.6K) — net selling of $5.6K. Since April 2021, Trabud has recorded 43 Form 4 filings for OKUR: 24 buys ($36.4M) and 19 sells ($5.2M).
Source: SEC EDGAR Form 4
What stands out
- No OnKure Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 8 reported open-market sales totaled $5.6K.
Key Statistics (April 2021 – Sep 23, 2026)
Total Form 4 filings
43
SEC EDGAR
Insider filers
15
Insider buys (24)
$36.4M
Insider sells (19)
$5.2M
Insider sentiment
Net buyingNet insider flow of $31.2M in net buying since April 2021, and $5.6K in net selling over the last 12 months.
Recent OKUR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Nicholas A Saccomano | President and CEO | Sale | 87 | $2.97 | $258.76 | SEC ↗ |
| Sep 23, 2026 | Jason A. Leverone | Chief Financial Officer | Sale | 302 | $2.97 | $898.21 | SEC ↗ |
| Jun 24, 2026 | Nicholas A Saccomano | President and CEO | Sale | 86 | $4.40 | $378.08 | SEC ↗ |
| Jun 24, 2026 | Jason A. Leverone | Chief Financial Officer | Sale | 303 | $4.40 | $1.3K | SEC ↗ |
| Mar 24, 2026 | Nicholas A Saccomano | President and CEO | Sale | 86 | $4.16 | $357.46 | SEC ↗ |
| Mar 24, 2026 | Jason A. Leverone | Chief Financial Officer | Sale | 301 | $4.16 | $1.3K | SEC ↗ |
| Dec 24, 2025 | Nicholas A Saccomano | President and CEO | Sale | 87 | $2.97 | $258.19 | SEC ↗ |
| Dec 24, 2025 | Jason A. Leverone | Chief Financial Officer | Sale | 302 | $2.97 | $896.25 | SEC ↗ |
| Sep 24, 2025 | Nicholas A Saccomano | President and CEO | Sale | 88 | $2.62 | $230.87 | SEC ↗ |
| Sep 24, 2025 | Jason A. Leverone | Chief Financial Officer | Sale | 303 | $2.62 | $794.92 | SEC ↗ |
| Jun 25, 2025 | Nicholas A Saccomano | President and CEO | Sale | 88 | $2.38 | $209.81 | SEC ↗ |
| Jun 25, 2025 | Jason A. Leverone | Chief Financial Officer | Sale | 303 | $2.38 | $722.41 | SEC ↗ |
| May 19, 2025 | Bihua Chen | Other | Sale | 1.8M | $1.85 | $3.4M | SEC ↗ |
| May 19, 2025 | Anders D Hove | 10% Owner | Purchase | 1.4M | $1.85 | $2.6M | SEC ↗ |
| May 14, 2025 | Bihua Chen | 10% Owner | Sale | 24.3K | $1.99 | $48.2K | SEC ↗ |
| Apr 8, 2025 | Nicholas A Saccomano | President and CEO | Sale | 874 | $2.94 | $2.6K | SEC ↗ |
| Apr 8, 2025 | Jason A. Leverone | Chief Financial Officer | Sale | 3.1K | $2.94 | $9.2K | SEC ↗ |
| Sep 26, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 98.3K | $1.47 | $144.7K | SEC ↗ |
| Sep 19, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 56.1K | $1.36 | $76.2K | SEC ↗ |
| Sep 16, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 358.9K | $1.35 | $484.3K | SEC ↗ |
| Aug 15, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 271.8K | $1.40 | $380.6K | SEC ↗ |
| May 16, 2024 | Braden Michael Leonard | 10% Owner | Purchase | 414.3K | $1.54 | $639.6K | SEC ↗ |
| Aug 29, 2023 | Ashley Hall | Chief Development Officer | Sale | 15.6K | $6.28 | $98.1K | SEC ↗ |
| Jun 23, 2023 | Novo Holdings A/S | 10% Owner | Sale | 100.0K | $7.10 | $709.7K | SEC ↗ |
| May 10, 2023 | Niall O'Donnell | Director | Purchase | 125.0K | $8.00 | $1.0M | SEC ↗ |
Showing the 25 most recent of 43 Form 4 filings for OnKure Therapeutics, Inc..
Most active OKUR insiders
- Bali Muralidhar8 filings
- Jason A. Leverone7 filings
- Nicholas A Saccomano7 filings
- Braden Michael Leonard5 filings
- Michael Cruse3 filings
Ask anything about OKUR insider activity
Use Trabud's AI agent to query OnKure Therapeutics, Inc.'s Form 4 history in plain English — "Show me OKUR CEO purchases this year" or compare it against any other ticker.
Open the AI agentOKUR insider trading FAQ
Are OnKure Therapeutics, Inc. insiders buying or selling?
In the last 12 months, OnKure Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 8 sales ($5.6K) — net selling of $5.6K. Since April 2021, Trabud has recorded 43 Form 4 filings for OKUR: 24 buys ($36.4M) and 19 sells ($5.2M). Over the full record that is net buying of $31.2M.
How many insiders trade OKUR stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for OnKure Therapeutics, Inc.. The most recent filing was accepted on Sep 23, 2026.
Where does Trabud get OKUR insider trading data?
All OKUR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.